Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia

Nineteen patients with high‐risk myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) received fludarabine, cytarabine, granulocyte‐colony stimulating factor (G‐CSF), and idarubicin chemotherapy (de novo MDS/MDS‐AML, nine; relapsed/refractory MDS/AML, seven; therapy‐related MDS, three). Medi...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1997-12, Vol.99 (4), p.939-944
Main Authors: Parker, J. E., Pagliuca, A., Mijovic, A., Cullis, J. O., Czepulkowski, B., Rassam, S. M. B., Samaratunga, I. R., Grace, R., Gover, P. A., Mufti, G. J.
Format: Article
Language:English
Subjects:
Acute Disease
Adolescent
Adult
Age
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
autologous stem cell transplantation
Biological and medical sciences
Blast
Blood
Bone marrow transplantation
Chemotherapy
chromosome 7
cytarabine
Cytarabine - administration & dosage
Cytarabine - adverse effects
Female
FLAG‐idarubicin
fludarabine
Follow-Up Studies
Granulocyte colony-stimulating factor
Granulocyte Colony-Stimulating Factor - administration & dosage
Granulocyte Colony-Stimulating Factor - adverse effects
Hematopoietic Stem Cell Transplantation
Humans
Idarubicin - administration & dosage
Idarubicin - adverse effects
Length of Stay
Leukemia, Myeloid - drug therapy
Leukocyte Count
Male
Medical sciences
Middle Aged
Myelodysplastic syndrome
Myelodysplastic Syndromes - drug therapy
Neutrophils
Pharmacology. Drug treatments
Platelet Count
Regeneration
Remission
Risk groups
Stem cells
Survival
Survival Rate
therapy‐related MDS
Treatment Outcome
Vidarabine - administration & dosage
Vidarabine - adverse effects
Vidarabine - analogs & derivatives
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nineteen patients with high‐risk myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) received fludarabine, cytarabine, granulocyte‐colony stimulating factor (G‐CSF), and idarubicin chemotherapy (de novo MDS/MDS‐AML, nine; relapsed/refractory MDS/AML, seven; therapy‐related MDS, three). Median age was 44 years and median disease duration 10 months. 16/19 (84%) patients had abnormal cytogenetics with seven (37%) harbouring abnormalities of chromosome 7. 18/19 (94.7%) patients responded to FLAG‐idarubicin with 12 (63%) achieving complete remission (CR) (
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1997.4763281.x